S R Aravind
Overview
Explore the profile of S R Aravind including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmedabad declaration: A framework to combat growing epidemic of young-onset type 2 diabetes in Asia
Parikh R, Saboo B, Misra A, Basit A, Aravind S, Bhowmik B, et al.
Diabetes Metab Syndr
. 2025 Mar;
19(2):103205.
PMID: 40054119
Aim: Rising prevalence of Type 2 Diabetes (T2D) among young Asians has emerged as a public health crisis that threatens the long-term health, economic stability, and productivity of nations across...
2.
Cooper Z, Johnson L, Ali M, Patel S, Poongothai S, Mohan V, et al.
Diabet Med
. 2024 Jul;
41(12):e15412.
PMID: 39039715
Aims: Patient satisfaction is associated with positive diabetes outcomes. However, there are no identified studies that evaluate both patient- and clinic-level predictors influencing diabetes care satisfaction longitudinally. Methods: Data from...
3.
Das A, Saboo B, Chawla R, Aravind S, Rajput R, Singh A, et al.
Int J Diabetes Dev Ctries
. 2023 Jun;
:1-19.
PMID: 37360324
Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus (T2DM). Physicians consider modern SU (gliclazide and glimepiride)...
4.
Mohan V, Schmider W, Singh K, Rotthaeuser B, Mukherjee B, Aravind S
Indian J Endocrinol Metab
. 2022 Oct;
26(4):354-361.
PMID: 36185965
Background: We compared the pharmacokinetic exposure, efficacy, safety and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SAR-Mix) with its originator NovoMix 30 insulin aspart mix (NN-Mix) in adults...
5.
Zargar A, Kalra S, Kumar K M P, Murthy S, Negalur V, Rajput R, et al.
Diabetes Metab Syndr
. 2022 Jul;
16(8):102528.
PMID: 35863268
Background And Aims: The rapid increase in burden of type 2 diabetes mellitus (T2DM), poses a huge medico-economic challenge, especially when the cost of care is funded by out-of-pocket expenses....
6.
Aravind S, Singh K, Mogylnytska L, Zalevskaya A, Matyjaszek-Matuszek B, Wernicke-Panten K, et al.
Diabetes Ther
. 2022 Jun;
13(7):1299-1310.
PMID: 35650350
Introduction: We compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (70% intermediate SAR341402 protamine and 30% rapid SAR341402 solution) (SAR-Mix) with its originator NovoMix...
7.
Saboo B, Misra A, Kalra S, Mohan V, Aravind S, Joshi S, et al.
Diabetes Metab Syndr
. 2022 May;
16(5):102480.
PMID: 35594690
Background & Aims: India is facing a triple burden of pre-diabetes, diabetes, and obesity. Unhealthy eating habits and physical inactivity have been linked to the onset and progression of type...
8.
Aravind S, Singh K, Aquitania G, Mogylnytska L, Zalevskaya A, Matyjaszek-Matuszek B, et al.
Diabetes Ther
. 2022 Apr;
13(5):1053-1071.
PMID: 35420397
Introduction: This study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SAR-Mix) with European-approved insulin aspart mix 70/30 - NovoMix® 30 (NN-Mix) in people...
9.
Joseph M, Aravind S, George S, Pillai R, Mini S, Sreelekha T
Eur J Pharm Biopharm
. 2021 Mar;
161:1-3.
PMID: 33722352
No abstract available.
10.
Prasanna Kumar K, Seshadri K, Aravind S, Deb P, Modi K, Gopal R, et al.
Cureus
. 2021 Mar;
13(1):e13020.
PMID: 33665047
Background Type 2 diabetes mellitus (T2DM) is associated with a significant burden on both patients and the healthcare system. This study aimed to evaluate the demographics of patients with T2DM ...